Evidence map›Paper›PMID 31316146›Full record

ArticleScientific reports2019

Chemopreventive Effect of Phytosomal Curcumin on Hepatitis B Virus-Related Hepatocellular Carcinoma in A Transgenic Mouse Model.

Chiao-Fang Teng, Chun-Hui Yu, Hong-Yi Chang, Wen-Chuan Hsieh, Tzu-Hua Wu, Jia-Hui Lin, Han-Chieh Wu, Long-Bin Jeng, Ih-Jen Su

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chiao-Fang TengGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Chun-Hui YuDepartment of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
Hong-Yi ChangDepartment of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
Wen-Chuan HsiehNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
Tzu-Hua WuOrgan Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Jia-Hui LinGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Han-Chieh WuNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
Long-Bin JengOrgan Transplantation Center, China Medical University Hospital, Taichung, Taiwan.ORCID http://orcid.org/0000-0002-4588-2268
Ih-Jen SuDepartment of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan. suihjen0704@stust.edu.tw.
China Medical University · TWNational Health Research Institutes · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B virus (HBV) infection is a major risk factor for the development of hepatocellular carcinoma (HCC), a leading cause of cancer mortality worldwide. Hepatitis B X protein (HBx) and pre-S2 mutant have been proposed as the two most important HBV oncoproteins that play key roles in HCC pathogenesis. Curcumin is a botanical constituent displaying potent anti-inflammatory and anti-cancer properties without toxic side effects. Phytosomal formulation of curcumin has been shown to exhibit enhanced bioavailability, improved pharmacokinetics, and excellent efficacy against many human diseases. However, effectiveness of phytosomal curcumin for HCC treatment remains to be clarified. In this study, we evaluated chemopreventive effect of phytosomal curcumin on HBV-related HCC by using a transgenic mouse model specifically expressing both HBx and pre-S2 mutant in liver. Compared with unformulated curcumin, phytosomal curcumin exhibited significantly greater effects on suppression of HCC formation, improvement of liver histopathology, decrease of lipid accumulation and leukocyte infiltration, and reduction of total tumor volume in transgenic mice. Moreover, phytosomal curcumin exerted considerably stronger effects on activation of anti-inflammatory PPARγ as well as inhibition of pro-inflammatory NF-κB than unformulated curcumin. Furthermore, phytosomal curcumin showed a comparable effect on suppression of oncogenic mTOR activation to unformulated curcumin. Our data demonstrated that phytosomal curcumin has promise for HCC chemoprevention in patients with chronic HBV infection.

Indexed as

AnimalsAnticarcinogenic AgentsChemopreventionCurcuminDrug CompoundingHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHumansLiverLiver Neoplasms, ExperimentalMaleMiceMice, Inbred C57BLMice, TransgenicMutationAnticarcinogenic AgentsCurcuminHepatitis B Surface Antigenshepatitis B virus X proteinpresurface protein 2, hepatitis B surface antigenProtein PrecursorsTrans-ActivatorsViral Regulatory and Accessory Proteins

Identifiers

PMID31316146
PMCPMC6637187
OpenAlexW2960949990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.